A first-of-its-kind Phase 3b study has shown that combining Eli Lilly’s Taltz (ixekizumab) with Zepbound (tirzepatide) delivers superior benefits for adults living with both active psoriatic arthritis (PsA) and obesity…
In 2005, the U.S. Food and Drug Administration (FDA) approved abatacept for the treatment of moderate-to-severe rheumatoid arthritis. Twelve years later, in 2017, the FDA expanded the drug's approval…
The European Congress of Rheumatology (EULAR) took place from May 31 - June 3, 2023. During the Congress, experts in rheumatology came together to discuss research, new guidelines, and…
From November 10-14, 2022, various stakeholders within the rheumatology sphere connected at the American College of Rheumatology’s (ACR) Convergence 2022. During ACR Convergence, described as the world’s premier rheumatology experience,…
People within the rare disease community face many barriers in regard to the diagnostic process. It can take years to receive an accurate diagnosis. Paired with medical costs and…
A recent article at Healio Rheumatology highlights a presentation given by Dr. Arthur Kavanaugh of the University of California to attendees at the 2022 Clinical Rheumatology Congress East. Dr. Kavanaugh…
Recently, two medical professionals were interviewed where they discussed their recommendations for the guidelines pertaining to managing psoriatic arthritis. Psoriatic Arthritis Psoriatic arthritis is a type of inflammatory arthritis that…
One thing that we know about psoriatic disease (a term that refers to both psoriatic arthritis and psoriasis) is that is linked to a heightened risk of cardiovascular (CV) mortality…
In the past, psoriatic arthritis (PsA) has been relatively difficult to manage or control with current therapies such as biologic disease-modifying anti-rheumatic drugs (bDMARDs). While some patients respond well to…
An estimated 30% of patients with psoriasis go on to develop psoriatic arthritis (PsA), a type of inflammatory arthritis that can affect joints throughout the body. One particular spot which…
The month of August is recognized as Psoriasis Awareness Month, a time of year set aside to help spread awareness about the disease among the general public and in the…
A recent study presented in early June showcased how, despite some similarities, psoriatic arthritis with axial involvement (axial PsA) patients and axial spondyloarthritis (axSpA) patients have meaningful differences. These findings…
How effective is guselkumab, a human monoclonal antibody, at treating patients with psoriatic arthritis (PsA)? According to post-hoc data analysis from two clinical trials, the therapy was relatively effective.…
On April 1, 2021, biopharmaceutical company AbbVie shared that new data is available from the Phase 3 SELECT-PsA 1 clinical trial. The 24-week results follow the impact of RINVOQ (upadacitinib)…
by Lauren Taylor from In The Cloud Copy Spondyloarthropathies is an umbrella term for a group of chronic diseases that affect the joints. These can affect children and adults and…
Michael George and his team from the University of Pennsylvania have recently uncovered new insights regarding autoimmune patient’s comfortability with care during COVID-19. They've been working since the pandemic began…
The annual meeting of the American College of Rheumatology was recently held, where data was presented on Cimzia and Bimekizumab. Not only were both of these therapies found to benefit…
From November 5 through 9th, the American College of Rheumatology (ACR) held their ACR Convergence 2020. Though the annual meeting took place online, it was still rife with insights into…
A recent study published in BMC Rheumatology has found that a combination therapy could have a benefit for individuals diagnosed with diabetes and ankylosing spondylitis (AS), psoriatic arthritis (PsA), or rheumatoid arthritis…
Recently, the Janssen Pharmaceutical Companies of Johnson & Johnson ("Janssen") announced the FDA approval of Simponi Aria (golimumab). The therapy is designed to treat pediatric patients (ages 2 or older)…
Caroline Wozniacki has led an interesting life. Born in Denmark, she was immediately thrust into athleticism. Her father was a former football player (that's soccer for you Americans) and her…
Following positive data from two Phase 3 trials, the European Commission (EC) approved Cosentyx (secukinumab) for the treatment of pediatric psoriasis. Drug developer Novartis announced the news early last…
In some cases, people have a medical condition that doesn't respond well to treatments. The journey to finding an effective treatment can be long and difficult. But for patients…
Celltrion Healthcare has just announced positive progress for extending the authorization for the subcutaneous (SC) form of Remsima to five more autoimmune conditions. These are- Psoriatic arthritis Ankylosing spondylitis (AS)…
According to LabioTech, a psoriasis drug developed by biotechnology company Affibody showed promising results in a Phase II clinical trial (AFFIRM-35). This trial, which consisted of 108 participants with…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
